Wyeth pharmaceuticals, one of the largest pharmaceutical companies in the world, have filed a new drug application to the U.S Food and Drug Administration and a marketing authorization application to the European Medicines Agency, for its new drug Torisel, which would be used for treating renal cell carcinoma. Torisel is an experimental drug, which specifically inhibits the activity of mTOR kinase, an enzyme, which regulates cell proliferation and cell survival.


The lead investigator of phase-3 trial of Torisel said that this drug could help in extending the lifespan of patients suffering from advanced-stage renal cell carcinoma, who would otherwise constantly require new treatment options for their survival. Renal cell carcinoma is a common form of Kidney cancer, which arises from the renal tubule or the nephron.

Read more of this story…


For more cancer news click here

Be Sociable, Share!